Abstract
Lynne Mofenson and Heather Watts discuss the context and implications of the study by J. Sibuide and colleagues, which provides a detailed analysis of birth defects in infants with in utero antiretroviral drug exposure in the French Perinatal Cohort. Please see later in the article for the Editors' Summary.
Highlights
There has been striking progress in reducing mother-to-child HIV transmission (MTCT) in resourceconstrained countries, with 1 million children prevented from acquiring HIV between 2003 and 2013 because of maternal and infant antiretroviral prophylaxis [3]
This Perspective discusses the following new study published in PLOS Medicine: Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag-Bonnet N, et al (2014) Association between Prenatal Exposure to Antiretroviral Therapy and Birth Defects: An Analysis of the French Perinatal Cohort Study (ANRS CO1/CO11)
Jeanne Sibiude and colleagues use the French Perinatal Cohort to estimate the prevalence of birth defects in children born to HIVinfected women receiving antiretroviral therapy during pregnancy
Summary
This Perspective discusses the following new study published in PLOS Medicine: Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag-Bonnet N, et al (2014) Association between Prenatal Exposure to Antiretroviral Therapy and Birth Defects: An Analysis of the French Perinatal Cohort Study (ANRS CO1/CO11). Jeanne Sibiude and colleagues use the French Perinatal Cohort to estimate the prevalence of birth defects in children born to HIVinfected women receiving antiretroviral therapy during pregnancy. Sibiude and colleagues in this week’s issue of PLOS Medicine provide a detailed analysis related to birth defects in infants with in utero antiretroviral drug exposure in the French Perinatal Cohort [5]. Given the emphasis on early treatment of HIV in adults and the move toward initiation of life-long therapy in all pregnant women in many resource-constrained countries, it can be anticipated that there will be a dramatic increase over time in women who conceive while receiving antiretroviral drugs, with fetal exposure from conception onward. There are only limited data on potential toxicities of fetal/infant antiretroviral drug exposure
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
